Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8:e1027–37.

Article  PubMed  Google Scholar 

Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38:698–707.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

Article  Google Scholar 

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7: e1000279.

Article  PubMed  PubMed Central  Google Scholar 

Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29:2301–4.

Article  PubMed  PubMed Central  Google Scholar 

Gyorffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11.

Article  PubMed  PubMed Central  Google Scholar 

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013;109:2959–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14:1067–76.

Article  PubMed  PubMed Central  Google Scholar 

Filipits M, Nielsen TO, Rudas M, Greil R, Stoger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.

Article  CAS  PubMed  Google Scholar 

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015;33:916–22.

Article  CAS  PubMed  Google Scholar 

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:545–53.

Article  PubMed  PubMed Central  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.

Article  PubMed  PubMed Central  Google Scholar 

Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 2021;7:370–8.

Article  PubMed  Google Scholar 

Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113:390–9.

Article  PubMed  Google Scholar 

Jung J, Hwang KT, Choi IS, Kim BH, Oh S, Kim J, et al. Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database. Breast Cancer. 2022;29:889–98.

Article  PubMed  Google Scholar 

Gong G, Kwon MJ, Han J, Lee HJ, Lee SK, Lee JE, et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. Sci Rep. 2017;7:45554.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwon MJ, Lee SB, Han J, Lee JE, Lee JW, Gong G, et al. BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLoS ONE. 2018;13: e0207155.

Article  PubMed  PubMed Central  Google Scholar 

Kwon MJ, Ryu JM, Cho SY, Nam SJ, Kim SW, Lee J, et al. Validation of the GenesWell BCT score in Young Asian women with HR+/HER2- early breast cancer. Front Oncol. 2021;11: 588728.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, et al. Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J Clin Oncol. 2016;34:2350–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 2017;19:120.

Article  PubMed  PubMed Central  Google Scholar 

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, et al. Prediction of distant recurrence using EndoPredict among women with ER(+), HER2(-) node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res. 2019;25:3865–72.

Article  CAS  PubMed  Google Scholar 

Kwon MJ, Lee JE, Jeong J, Woo SU, Han J, Kang BI, et al. Comparison of GenesWell BCT score with Oncotype DX recurrence score for risk classification in Asian women with hormone receptor-positive, HER2-negative early breast cancer. Front Oncol. 2019;9:667.

Article  PubMed  PubMed Central  Google Scholar 

Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010;116:3112–8.

Article  CAS  PubMed  Google Scholar 

Yamauchi H, Nakagawa C, Takei H, Chao C, Yoshizawa C, Yagata H, et al. Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. Clin Breast Cancer. 2014;14:191–7.

Article  PubMed  Google Scholar 

Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, et al. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol. 2010;40:508–12.

Article  PubMed  Google Scholar 

Shimizu H, Horimoto Y, Arakawa A, Sonoue H, Kurata M, Kosaka T, et al. Application of a 70-gene expression profile to Japanese breast cancer patients. Breast Care (Basel). 2015;10:118–22.

Article  PubMed  Google Scholar 

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat. 2011;128:633–41.

Article  PubMed  Google Scholar 

Tsukamoto F, Arihiro K, Takahashi M, Ito KI, Ohsumi S, Takashima S, et al. Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer. BMC Cancer. 2021;21:1077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111:1298–306.

Article  CAS  PubMed  PubMed Central  Google Scholar